Avanafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction in adult males.
The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cGMP, producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. Avanafil has no direct relaxant effect on isolated human corpus cavernosum, but enhances the effect of NO by inhibiting PDE5, which is responsible for degradation of cGMP in the corpus cavernosum. Because sexual stimulation is required to initiate the local release of nitric oxide, the inhibition of PDE5 has no effect in the absence of sexual stimulation. Studies in vitro have shown that avanafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (greater than 100-fold for PDE6; greater than 1,000-fold for PDE4, PDE8 and PDE10; greater than 5,000-fold for PDE2 and PDE7; greater than 10,000-fold for PDE1, PDE3, PDE9, and PDE11). Avanafil is greater than 100-fold more potent for PDE5 than PDE6, which is found in the retina and is responsible for phototransduction. In addition to human corpus cavernosum smooth muscle, PDE5 is also found in other tissues including platelets, vascular and visceral smooth muscle, and skeletal muscle, brain, heart, liver, kidney, lung, pancreas, prostate, bladder, testis, and seminal vesicle. The inhibition of PDE5 in these tissues by avanafil may be the basis for the enhanced platelet anti-aggregatory activity of NO observed in vitro and peripheral vasodilatation in vivo.
Rakshit is a leading manufacturer and supplier of Active Pharmaceutical Ingredients (APIs) through our manufacturing sites in Hyderabad and Vizag. Our API facilities have been inspected and approved by different international regulatory bodies including the US FDA, Japan PMDA, KFDA, TGA and meet the cGMP standards. We have sustainably evolved as one of the fast growing organization in the pharmaceutical industry in India. To cater to market requirements, we have dedicated our 6 manufacturing facilities to our core business area – APIs ably supported well-equipped Research & Development laboratory both for process improvement and new product development.
We have been successfully supplying APIs all over the globe for more than Two decades. We are capable of executing extensive API requirements for our customers. Rakshit has an experienced team of skilled employees, who are equipped for API manufacture with adequate care. We have a stand-alone R&D center located in Visakhapatnam with State-of-the-art analytical facilities and around 100 employees. We have wide variety of products in diverse therapeutic segments.
Some of the Active Pharmaceuticals Ingredients (APIs) mentioned in the Rakshit’s product list or brochure or in the product list uploaded in Rakshit’s website may be protected by a valid patent in India or in any other countries concerned. However, mentioning of the name of such product(s) in the product brochure or the product list shall not be construed as infringement in any manner whatsoever. Without prejudice to the foregoing, Rakshit’s supply of API being protected by a valid product patent, if any, is intended solely for uses reasonably relating to the research and development, and regulatory submission under any law for the time being inforce, in India, or in a country other than India that regulates the manufacture, use, sale or import of the said product, strictly under the conditions as set forth in Section 107A of the Indian patents Act, 1970, as amended in 2005, or an equivalent provision (Bolar exemption) thereof in a country other than India. The disclaimer is applicable till the expiration of the corresponding product patent(s), if any, in the respective countries concerned. None of the products will be supplied to the countries wherein this could be in conflict with existing laws. However, the final responsibility lies exclusively with the buyer/end customer